Minimally invasive reliAble Glucose monitoring in Intensive Care
"9 of 10 intensive care unit (ICU) patients get elevated glucose levels because of their critical illness. Clinical trials prove that better glucose control could save thousands of lives and millions of euros for hospitals. Surpri...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PTQ2021-012005
Nuevas herramientas biosensoras para el diagnóstico remoto,...
100K€
Cerrado
PDC2021-121470-C21
PREDICCION DE GLUCOSA SIN INTERVENCION DEL USUARIO PARA EL A...
69K€
Cerrado
TEC2014-61743-EXP
EXPLORACION DE UNA PROPUESTA TECNOLOGICA PARA LA PRODUCCION...
22K€
Cerrado
PREVENTDIABETES
The world’s first needle-free continuous glucose monitor to...
7M€
Cerrado
DPI2010-20764-C02-01
NUEVAS ESTRATEGIAS DE CONTROL GLUCEMICO POSTPRANDIAL MEDIANT...
267K€
Cerrado
DPI2010-20764-C02-02
NUEVAS ESTRATEGIAS DE CONTROL GLUCEMICO POSTPRANDIAL MEDIANT...
224K€
Cerrado
Información proyecto MAGIC
Duración del proyecto: 21 meses
Fecha Inicio: 2022-12-14
Fecha Fin: 2024-09-30
Líder del proyecto
SINTEF AS
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
5M€
Descripción del proyecto
"9 of 10 intensive care unit (ICU) patients get elevated glucose levels because of their critical illness. Clinical trials prove that better glucose control could save thousands of lives and millions of euros for hospitals. Surprisingly, no continuous glucose monitor (CGM) is available for ICU patients, as solutions developed for diabetics don't work in the ICU.
GlucoSet has a novel, patented technology for glucose monitoring. This enables - for the first time - reliable, minimally invasive, real-time monitoring of glucose in ICU patients. 4 of 5 EU ICU physicians say our product would be ""very valuable"" in their ICU and believe it will improve outcomes in their ICU. 9 of 10 ICU managers say they are willing to pay for use in a large share of their patients on launch.
A demo version of the product has been tested in patients with excellent results (TRL6). This project aims to make the product ready for CE-mark (TRL8) in 22 months, then validate clinical benefits, and scale up (TRL9)."